A polymeric aqueous tacrolimus formulation for topical ocular delivery

Tacrolimus (TAC) suspension is used to treat moderate severe atopic keratoconjunctivitis (AKC) and vernal (VKC). The objectives of this study were formulate the hydrophobic compound TAC in an aqueous eye drop formulation its ocular biodistribution on topical application a healthy rabbit model, with overall aim using AKC VKC. A thin-film hydration method was encapsulate within chitosan-based amphiphile: N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (Molecular Envelope Technology – MET) formulation. characterized, stability studied under three storage conditions for one month. distribution rabbits tissues whole blood analyzed by LC-MS/MS. 200 nm nanoparticle (MET-TAC) containing 0.1 ± 0.002% w/v produced viscosity, osmolarity pH comfort range, stable refrigeration On application, concentrations cornea conjunctiva hour after dosing 4452 2289 516 180 ng/g tissue, respectively. has been prepared ability deliver sufficient drug relevant surface tissues.